A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
Sponsor: Sanofi/Abbvie
Protocol Number: BCC-VID-2022
Start Date: Early 2024
Not active
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
Sponsor: Sanofi/Abbvie
Protocol Number: BCC-VID-2022
Start Date: Early 2024
Not active